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Abstract S100A2, a calcium binding protein of the EF-hand
family, was recently identified to be inducible by etoposide, a p53
activator. A potential p53 binding site was identified in the
promoter of the S100A2 gene, which binds to purified p53 as well
as p53 in nuclear extract activated by etoposide. Transactivation
assays using the promoter driven luciferase reporters revealed
that the S100A2 promoter was transcriptionally activated by
wild-type p53, but not by p53 mutants, in a dose-dependent as
well as a p53 binding site-dependent manner. The p53-induced
transactivation of the S100A2 promoter was enhanced by
etoposide and blocked by a dominant negative p53 mutant.
Furthermore, endogenous S100A2 mRNA expression is induced
by etoposide in p53 positive, but not in p53 negative cells. Thus,
p53 appears to positively regulate S100A2 expression.
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1. Introduction
p53 is a transcription factor and a tumor suppressor [1]. As
a transcription factor, p53 binds to it’s consensus binding
sequence (two copies of the 10 bp motif 5P-PuPuPuC(A/
T)(T/A)GPyPyPy-3P, separated by 0^13 bp) [2] and transacti-
vates a set of target genes. As a tumor suppressor, p53 induces
either growth arrest or apoptosis [1]. These biological func-
tions of p53 are mainly mediated through the activation of
downstream target genes. For example, p53-induced growth
arrest is mainly achieved through activation of p21/Waf-1 [3],
whereas p53-induced apoptosis is mediated by or associated
with activation of Bax [4], Fas/APO1 [5], KILLER/DR5 [6]
and genes involved in generation of reactive oxygen species
[7]. Also, potential e¡ects of p53 in tumor metastasis are
mediated through regulation of metastasis-related genes
[8,9]. Thus, identi¢cation of genes whose expression is sub-
jected to p53 regulation would lead to a better understanding
of p53 functions and its mechanism of action.
In an attempt to identify novel p53 target genes, we treated
p53 positive cells with etoposide, a topoisomerase II inhibitor
and a p53 activator [8]. Global changes of gene expression
were monitored by DNA chip hybridization [10]. Through
this approach, we have identi¢ed that S100A2, a calcium
binding protein [11,12], is inducible by etoposide [10]. We
report here the characterization of p53 regulation of the
S100A2 promoter and suggest that the S100A2 is a novel
p53 target gene.
2. Materials and methods
2.1. Cell culture and drug treatment
Two human osteogenic sarcoma cell lines, U2-OS and Saos-2
(ATCC), were grown in McCory or DMEM supplemented with
10% FCS, respectively. U2-OS cells harbor a wild-type p53 [13],
whereas Saos-2 cells have the p53 gene deleted [14]. For drug treat-
ment, U2-OS and Saos-2 cells were exposed to etoposide (25 WM,
Sigma) for various periods of time up to 48 h.
2.2. Gel shift assay
The assay was performed as described previously [15], using as the
probe a 20 bp synthetic oligonucleotide, S100A2.01 (5P-GGGCATG-
TGTGGGCACGTTC-3P), consisting of the putative p53 binding site
identi¢ed in the S100A2 promoter and its complementary strand.
2.3. Luciferase reporter constructions
The luciferase reporter constructs driven by the S100A2 promoter
were made as follows. (a) S100A2 W/p53BS: a 2269 bp DNA frag-
ment of the S100A2 promoter containing the p53 binding site and (b)
S100A2 W/O p53BS: a 2060 bp DNA fragment of the S100A2 pro-
moter without p53 binding site, were generated by PCR ampli¢cation
from a cloned promoter fragment [16]. The primers used are: PA23-
Hind (downstream primer): 5P-CTGAAGCTTGGCAGAGACA-
GACCCAGGAAG-3P ; PA25Xho (with p53 site, upstream primer):
5P-CTGCTCGAGTTTGTACAGGACAGAACAGGTAGA-3P ; and
KA25Xho (without p53 binding site, upstream primer): 5P-AGACTC-
GAGGGACACGCAGCAGCAGGCC-3P. The PCR fragments were
subcloned into pGL-Basic-3 luciferase reporter plasmid (Promega) at
the restriction sites of XhoI (5P) and HindIII (3P).
2.4. DNA transfection and luciferase assay
Dispersed cells were seeded into 24 well plates at a concentration of
105 cells (Saos-2) or 2U105 cells (U2-OS) per well 16^24 h prior to
transfection. The calcium phosphate method was used to transiently
transfect Saos-2 cells [15], whereas the lipofectamine method (BRL)
was used for U2-OS transfection according to the manufacturer’s
instructions. The luciferase reporter constructs described above, along
with the empty vector plasmid, were co-transfected with a L-galacto-
sidase construct in the presence or absence of constructs expressing
wild-type or mutant p53 proteins. 38 h post transfection, cells were
lysed and assayed for luciferase/L-galactosidase activities [17]. The
results are presented as the fold activation over empty reporter after
normalizing the L-galactosidase activity.
2.5. Northern analysis
Total RNA was isolated from etoposide-treated cells using RNAzol
solution (Tel-Test). 15 Wg of total RNA was subjected to Northern
analysis [18].
3. Results and discussion
3.1. Speci¢c binding of wild-type p53 to the p53 binding site
identi¢ed in the S100A2 promoter
Through DNA chip hybridization, we have recently shown
that S100A2 is an etoposide-inducible gene [10]. A putative
p53 binding site, 5P-GGGCATGTGTGGGCACGTTC-3P
(underlined are two mismatches to the consensus sequence),
located at 33811 bp upstream from the translation initiation
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site was identi¢ed. To examine whether p53 is able to bind to
this putative binding site, we used both puri¢ed p53 protein
[17] and nuclear extract from p53 positive U2-OS cells treated
with etoposide (25 WM) for 0, 6 or 24 h. As shown in Fig. 1, a
20 bp oligonucleotide, consisting of the S100A2 p53 binding
site, binds to puri¢ed p53 only in the presence of p53 anti-
body, pAb421, that is known to enhance and stabilize p53
DNA binding [19] (compare lanes 1 and 2). Two binding
bands are revealed (as indicated by arrows), possibly re£ecting
di¡erent conformations [17]. The binding is sequence-speci¢c
since it can be blocked by a speci¢c (lane 3) but not by a non-
speci¢c cold oligonucleotide (lane 4). Endogenous p53 in un-
stimulated U2-OS is found not to be capable of binding to the
oligonucleotide due to the low protein level (lanes 5 and 6).
Upon activation by etoposide for 6 or 24 h, however, a strong
p53 binding is detected in the presence of antibody (lanes 8
and 10). Again, the binding is sequence-speci¢c and can be
blocked by addition of an excess of unlabelled speci¢c oligo-
nucleotide (lane 11), but not by a non-speci¢c control oligo-
nucleotide (lane 12). The result indicates that p53 can bind to
the putative p53 binding site in the S100A2 promoter.
3.2. Transactivation of the S100A2 promoter by p53 is both
p53 dose- and p53 binding site-dependent
We ¢rst examined whether p53 transactivates the S100A2
promoter and whether activation is p53 dose-dependent. We
generated a luciferase reporter construct driven by a 2269 bp
promoter fragment containing the p53 binding sites (S100A2
W/p53BS) and used it in a transactivation/luciferase assay.
The result shows that p53 does transactivate the S100A2 pro-
moter and transactivation is p53 dose-dependent (data not
shown). We next examined whether p53-induced transactiva-
tion of the S100A2 promoter is p53 binding site-dependent.
We compared luciferase activity in the constructs driven by
the S100A2 promoter sequence with (S100A2 W/p53BS) or
without (S100A2 W/O p53BS) p53 binding site in Saos-2 cells
after transiently co-transfected with a p53 expressing plasmid
or an empty vector as the control. As shown in Fig. 2, in the
absence of p53 (vector control), both constructs produce a
comparable promoter activity, giving rise to a 8^10-fold high-
er luciferase activity than that of the empty vector. Most
likely, this activity re£ects the level of endogenous S100A2
expression generated by the enhancer element identi¢ed earlier
[16]. In the presence of p53, the construct without p53 binding
site gives rise to a similar level of luciferase activity. However,
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Fig. 1. p53 binds to a putative p53 binding site in the promoter of
the S100A2 gene: synthetic oligonucleotides consisting of the p53
binding consensus sequence were labelled with [Q-32P]ATP using T4
polynucleotide kinase and used in a gel shift assay [15,17]. Lanes 1^
4, partially puri¢ed p53 (3 Wg) with or without pAb421 antibody
and lanes 5^12, nuclear extracts (8.5 Wg) prepared from cells treated
with etoposide (25 WM) for 0 h (lanes 5 and 6), 6 h (lanes 7 and 8)
and 24 h (lanes 9^12). Competition was performed with a 100-fold
excess of speci¢c oligonucleotide S100A2.01, or non-speci¢c oligonu-
cleotide mT3SF (5P-GGGGTTGCTTGAAGAGCGTC-3P). The p53-
Ab supershifted bands are indicated by the arrows. The band shown
on the bottom of the gel is free labelled probe.
Fig. 2. p53 binding site-dependent activation of the S100A2 pro-
moter. Two luciferase reporter constructs driven by the S100A2 pro-
moter with (S100A2 W/p53BS) or without (S100A2 W/O p53BS)
the p53 binding site were transiently co-transfected with or without
p53 expressing plasmid, respectively, into human Saos-2 cells. The
results are presented as fold activation þ S.D. derived from three in-
dependent transfections, each run in duplicate, after normalization
with the L-galactosidase activity for the transfection e⁄ciency.
Fig. 3. Tumor-derived p53 mutants do not transactivate the S100A2
promoter. The constructs S100A W/p53BS and S100A2 W/O p53BS
were transiently co-transfected, respectively, with plasmids express-
ing p53 mutants into human Saos-2 cells. The results are presented
as fold activation þ S.D. derived from three independent transfec-
tions and assays, each run in duplicate, after normalization with the
L-galactosidase activity for the transfection e⁄ciency.
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the p53 binding site-containing construct induces a 35-fold
activation of luciferase activity. Hence, p53 can stimulate pro-
moter activity 3.5-fold over background levels. These results
indicate that transactivation of the S100A2 promoter by p53
is p53 binding site-dependent.
3.3. Lack of transactivation of the S100A2 promoter by p53
mutants
We further examined whether the S100A2 promoter activity
could also be stimulated by p53 mutants. Plasmid DNAs ex-
pressing p53 mutant proteins were individually co-transfected
with luciferase reporters into Saos-2 cells. Mutants used are
p53-143A, p53-175H, p53-248W, p53-273H, p53-281G, ¢ve of
the most common p53 mutants in human cancers [20] and
p53-280T, a dominant negative p53 mutant found in naso-
pharyngeal carcinomas [21^23]. As shown in Fig. 3, no sig-
ni¢cant induction of luciferase activity is observed by any of
the p53 mutants. These results indicate that all p53 mutants
have lost the ability to transactivate the S100A2 promoter.
3.4. Induction of p53-dependent transactivation by etoposide
Etoposide has been previously shown to activate p53 in U2-
OS cells [8]. We therefore examined whether etoposide would
induce p53-dependent transactivation of the S100A2 pro-
moter. As shown in Fig. 4 (top panel), transactivation of
the luciferase reporter driven by the p53 site-containing pro-
moter is induced by etoposide with a 3-fold induction
achieved at 48 h. A slight induction of the luciferase activity
was also seen in the p53 site-deleted promoter that appears to
be p53-independent. To con¢rm that etoposide-induced trans-
activation is largely p53-dependent, we transfected p53-280T,
a known dominant negative p53 mutant [21^23] into U2-OS
cells, followed by etoposide treatment. As a control, the
empty vector was used. As shown in Fig. 4 (bottom panel),
etoposide-induced activation is abolished by p53-280T
(S100A2 W/p53BS+p53-280T) to a level comparable with
that of S100A2 W/O p53BS (Fig. 4, top panel), but it is not
inhibited by the vector control (S100A2 W/p53BS+Vector).
These results demonstrate that transactivation of the
S100A2 promoter by etoposide is largely p53-dependent.
3.5. Induction of S100A2 mRNA expression by etoposide in
p53 positive, but not in p53 negative cells
To examine whether endogenous S100A2 is subjected to
p53 regulation, we treated p53 positive U2-OS cells and p53
negative Saos-2 cells with etoposide. As shown in Fig. 5, there
is a basal level of S100A2 mRNA in U2-OS cells, which is
induced by a 3-fold after exposure to etoposide for 24 h. In
Saos-2 cells, S100A2 mRNA is not detectable at the basal
level and no induction is observed by etoposide. The result
indicates a p53 status-dependent regulation of S100A2 expres-
sion.
S100A2 is an EF-hand calcium binding protein that has
been associated with the development of malignancies through
its down-regulation during tumor progression [12,24]. This
down-regulation has previously been suggested to depend
upon the DNA methylation status in the promoter region
[16,25]. On the other hand, as shown in this report, the
S100A2 promoter activity can also be in£uenced by the p53
status of tumor cells. Hence, the loss of S100A2 expression in
tumor cells is mediated by at least two independent mecha-
nisms. The ¢nding that the S100A2 promoter is subjected to
positive regulation by wild-type p53, but not by any p53 mu-
tants appears to be signi¢cant since it links the p53 signalling
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Fig. 4. Induction of p53-dependent transactivation of the S100A2
promoter by etoposide. Subcon£uent U2-OS cells were co-trans-
fected with S100A2 W/p53BS or W/O p53BS luciferase reporters
(top) and p53 mutant expressing construct (p53-280T) or the vector
control (bottom). Cells were treated with etoposide (25 WM) 24 h
post transfection for 0, 2, 6, 12, 24 or 48 h, respectively, followed
by luciferase activity measurements. Three independent transfections,
each run in duplicate, were performed and results are presented as
fold activation þ S.D. after normalization with the L-galactosidase
activity for the transfection e⁄ciency. To calculate the fold activa-
tion, the luciferase activity from the S100A2 W/O p53BS construct
(top) or from the S100A2 W/p53BS construct (bottom) after 0 h
etoposide treatment was arbitrarily set as 1.
Fig. 5. Induction of endogenous S100A2 mRNA expression by eto-
poside in p53 positive cells. Total RNA was isolated from p53 posi-
tive U2-OS and p53 negative Saos-2 cells treated with etoposide (25
WM) for 0, 6 or 24 h and subjected (15 Wg) to Northern analysis.
The fold change after normalization with GAPDH is listed on the
bottom of the ¢gure.
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pathway to the calcium signalling pathway, both of which are
involved in apoptosis [26,27]. It could imply that S100 family
members mediate p53 apoptosis signals. Indeed, S100B, a sec-
ond S100 family member was recently found to functionally
interact with p53 in the regulation of p53-dependent cell
growth arrest and apoptosis [28]. Interestingly, the expression
of S100B was also increased in cells expressing wild-type p53
in response to UV irradiation [28,29]. Since S100A2 is a nu-
clear protein [11], it might also be possible that it can func-
tionally interact with p53 as shown for S100B [28,29]. Thus,
our ¢nding that S100A2 is a novel p53 target gene suggests
possible concerted functions of S100A2 and p53 in mediating
the tumor suppressor role of p53.
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